Albeit at similar lines with our results, still these data may be considered only as indicative, given that (i) the number of CR-PCa patients analyzed was very small, and (ii) the HLA-A2 phenotype was defined with a monoclonal antibody also recognizing HLA-B*57/B*58 (expressed by about 5% of the Swedish population) and not discriminating among the HLA-A2 sub-alleles (e.g., A*02:01 from others). This evidence concerns the gene HLA-B and posterior cortical atrophy.